Tirzepatide dosage belongs to a clinical plan
A paper records what a research team tested. Its treatment plan is evidence to interpret, not a set of personal instructions.

A trial describes a supervised plan
Tirzepatide dosage searches often start with a comparison against semaglutide. The first problem is that these are different molecules. An amount measured in milligrams cannot serve as a common score for their effects, and a ratio of amounts cannot establish an equivalent treatment.
A trial includes more than a quantity. It has entry rules, a defined population, monitoring, a schedule of assessments, and criteria for handling problems. Taking one treatment detail out of that setting removes the safeguards and the context in which the finding was observed.
Different studies used different comparisons
SURPASS-2 followed adults with type 2 diabetes for 40 weeks. It compared several tirzepatide study groups with one semaglutide group. Its main question concerned HbA1c, a blood test reflecting average blood sugar over recent months. The trial found greater average reductions with the tirzepatide groups tested.
SURMOUNT-5 asked about weight over 72 weeks in adults with obesity without type 2 diabetes. It used the maximum tolerated doses allowed by its research plan. Maximum tolerated means the study treatment an individual could remain on under that plan; it is not a goal suggested by this page.
Lilly funded that open-label trial, in which treatment assignments were known. Its larger average weight reduction with tirzepatide applies to the comparison actually tested. It does not validate a conversion chart, every formulation, or an individual prescription.
Amount and concentration are different
An amount is how much active ingredient is present. Concentration describes how much of that ingredient is in a given volume of liquid. The two terms answer different questions. Neither can be reconstructed safely from a study headline or an unnamed preparation.
FDA has reported errors involving unapproved GLP-1 medicines, including problems with measuring and calculating amounts. This page contains no calculation, administration directions, or switching schedule. The actual preparation and its instructions are necessary for a pharmacist or prescriber to resolve unclear wording.
The legal setting is product specific
FDA distinguishes compounded preparations from approved medicines. Compounded drugs are not FDA-approved; FDA does not check their safety, effectiveness, and quality before marketing in the same way. A prescription and a familiar ingredient name do not transfer a brand medicine's approval to another preparation.
FDA's GLP-1 compounding notices describe dated policies as supply changed. An older shortage statement cannot establish a continuing exception for every preparation. The relevant source and the exact product remain necessary for a current legal assessment.
A separate HHS draft published October 30, 2026 concerns BPC-157, TB-500, epitalon, KPV, MOTS-c, and semax. Its nonbinding enforcement-discretion policy states an intention not to take enforcement action under set conditions. Those conditions apply under 503A, the framework for compounding medicine for an individual patient's prescription, with only one active ingredient. It covers neither tirzepatide nor blends nor 503B outsourcing facilities, which compound larger batches. It is not FDA approval or a final decision on the 503A bulks list, the list of substances allowed for compounding under that framework.
Safety cannot be reduced to an amount
The tirzepatide label includes common stomach effects and serious warnings. Pancreatitis means inflammation of the pancreas. Vomiting and diarrhea can cause severe fluid loss, and dehydration can contribute to kidney injury. Other medicines and medical history also change the clinical context.
The label's boxed warning, its strongest form of warning, concerns thyroid C-cell tumors seen in rodents; whether these occur because of tirzepatide in humans is unknown. The label rules out use with a personal or family history of medullary thyroid cancer or MEN 2, an inherited condition.
The comparison page returns to the trial question. The FAQ explains the pharmacy name. Neither page evaluates a person, selects treatment, or turns published evidence into a prescription.
Trial wording is not an instruction sheet
A result can be accurately attributed to a trial while still being unsuitable as personal instructions. The research team defined treatment and monitoring together. This page therefore explains the design and its limits rather than reproducing amounts, a starting schedule, or a method for changing between medicines.